Amantadine
Amantadine, Gocovri (amantadine) is a small molecule pharmaceutical. Amantadine was first approved as Symmetrel on 1982-01-01. It is used to treat drug-induced akathisia, drug-induced dyskinesia, dystonia, human influenza, and parkinson disease amongst others in the USA. The pharmaceutical is active against glutamate receptor ionotropic, NMDA 2A, glutamate receptor ionotropic, NMDA 2B, glutamate receptor ionotropic, NMDA 2D, and glutamate receptor ionotropic, NMDA 2C.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Amantadine, Gocovri (discontinued: Amantadine, Osmolex, Symadine, Symmetrel)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amantadine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GOCOVRI | Supernus Pharmaceuticals | N-208944 RX | 2017-08-24 | 2 products, RLD, RS |
Show 4 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| amantadine | ANDA | 2025-07-28 |
| amantadine hcl | ANDA | 2025-06-24 |
| amantadine hydrochloride | ANDA | 2025-10-24 |
| gocovri | New Drug Application | 2025-10-22 |
| symmetrel hard gel | ANDA | 2023-01-18 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
AMANTADINE HYDROCHLORIDE, GOCOVRI, ADAMAS OPERATIONS | |||
| 2024-08-24 | ODE-153 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Amantadine Hydrochloride, Gocovri, Adamas Operations | |||
| 11065213 | 2038-08-23 | DP | |
| 11077073 | 2038-08-23 | U-2106, U-2224, U-3180 | |
| 10154971 | 2034-12-04 | U-2459 | |
| 10646456 | 2034-06-17 | U-2808 | |
| 8741343 | 2030-12-02 | U-2106 | |
| 9867791 | 2030-12-02 | U-2106 | |
| 9867792 | 2030-12-02 | U-2106 | |
| 9867793 | 2030-12-02 | U-2106 | |
| 9877933 | 2030-12-02 | U-2224 | |
| 11197835 | 2030-12-02 | U-2106 | |
| 8389578 | 2028-01-22 | U-219, U-2105, U-3054 | |
| 8796337 | 2025-11-23 | U-219, U-2106, U-2497, U-3054 | |
| 8889740 | 2025-11-23 | DP | |
| 8895614 | 2025-11-23 | DP | |
| 8895615 | 2025-11-23 | U-219, U-2106, U-3054 | |
| 8895616 | 2025-11-23 | U-219, U-2106, U-3054 | |
| 8895617 | 2025-11-23 | U-219, U-2106, U-3054 | |
| 8895618 | 2025-11-23 | DP | |
| Amantadine Hydrochloride, Osmolex Er, Adamas Operations | |||
| 10213393 | 2038-02-15 | U-20 | |
| 10213394 | 2038-02-15 | U-2497 | |
| 10500170 | 2038-02-15 | U-20 | |
| 10500171 | 2038-02-15 | U-2497 | |
| 10500172 | 2038-02-15 | U-2497 | |
| 10512617 | 2038-02-15 | U-2497 | |
| 8252331 | 2030-03-13 | DP | |
| 8574626 | 2025-11-28 | DP | U-20 |
| 8987333 | 2025-11-23 | DP | |
| 9072697 | 2025-11-23 | U-219, U-3054 | |
HCPCS
No data
Clinical
Clinical Trials
330 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 3 | 6 | 11 | 24 | 3 | 46 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 2 | 8 | 10 | 9 | 8 | 36 |
| Cognitive dysfunction | D060825 | — | G31.84 | 2 | 11 | 9 | 4 | 2 | 25 |
| Traumatic brain injuries | D000070642 | — | S06 | 1 | 3 | 4 | 5 | 7 | 18 |
| Dementia | D003704 | EFO_0003862 | F03 | — | 3 | 3 | 8 | 3 | 17 |
| Brain injuries | D001930 | — | S06.9 | 1 | 4 | 3 | 5 | 7 | 17 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 2 | 5 | 7 | 3 | 1 | 16 |
| Dyskinesias | D020820 | — | G24 | 2 | 4 | 6 | 1 | 2 | 14 |
| Sclerosis | D012598 | — | — | — | 7 | 7 | 1 | — | 13 |
| Healthy volunteers/patients | — | — | — | 8 | 1 | — | 2 | 1 | 12 |
Show 70 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | 3 | 4 | — | 1 | 9 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 5 | 4 | — | — | 9 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | 3 | — | 2 | 6 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | 5 | 2 | — | — | 5 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | — | 5 | 2 | — | — | 5 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | 1 | 3 | 2 | — | — | 5 |
| Compulsive personality disorder | D003193 | — | F60.5 | 1 | 3 | 2 | — | — | 5 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | 2 | — | 2 | 5 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 3 | 1 | — | — | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 3 | 1 | — | — | 4 |
Show 54 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Human influenza | D007251 | EFO_0007328 | J11.1 | 1 | 4 | — | — | 3 | 7 |
| Consciousness disorders | D003244 | — | — | 2 | 3 | — | — | — | 4 |
| Glioblastoma | D005909 | EFO_0000515 | — | 2 | 2 | — | — | 1 | 4 |
| Developmental disabilities | D002658 | EFO_0003852 | F89 | — | 3 | — | — | 1 | 4 |
| Asperger syndrome | D020817 | EFO_0003757 | F84.5 | — | 3 | — | — | 1 | 4 |
| Tobacco use disorder | D014029 | — | F17 | 2 | 1 | — | — | — | 3 |
| Dyslexia | D004410 | EFO_0005424 | F81.0 | — | 3 | — | — | — | 3 |
| Coma | D003128 | — | R40.2 | — | 1 | — | — | 2 | 3 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 3 | — | — | — | 3 |
| Post-acute covid-19 syndrome | D000094024 | — | — | — | 3 | — | — | — | 3 |
Show 36 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 2 | — | — | — | — | 2 |
| Gliosarcoma | D018316 | — | — | 1 | — | — | — | — | 1 |
| Crush injuries | D000071576 | — | T14.8 | 1 | — | — | — | — | 1 |
| Central nervous system diseases | D002493 | — | G96.9 | 1 | — | — | — | — | 1 |
| Sleep deprivation | D012892 | — | F51.12 | 1 | — | — | — | — | 1 |
| Constipation | D003248 | — | K59.0 | 1 | — | — | — | — | 1 |
| Nervous system neoplasms | D009423 | — | — | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Subdural hematoma | D006408 | — | — | 1 | — | — | — | — | 1 |
| Hematoma | D006406 | EFO_0010680 | — | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Shy-drager syndrome | D012791 | EFO_1001050 | — | — | — | — | — | 1 | 1 |
| Multiple system atrophy | D019578 | — | — | — | — | — | — | 1 | 1 |
| Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | — | — | — | — | 1 | 1 |
| Corticobasal degeneration | D000088282 | — | G31.85 | — | — | — | — | 1 | 1 |
| Respiratory tract diseases | D012140 | — | — | — | — | — | — | 1 | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | — | 1 | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | — | 1 | 1 |
| Respiration disorders | D012120 | — | J00-J99 | — | — | — | — | 1 | 1 |
| Disease progression | D018450 | — | — | — | — | — | — | 1 | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | — | — | 1 | 1 |
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Amantadine |
| INN | amantadine |
| Description | Amantadine is a member of the class of adamantanes that is used as an antiviral and antiparkinson drug. It has a role as an antiviral drug, an antiparkinson drug, a dopaminergic agent, an analgesic, a NMDA receptor antagonist and a non-narcotic analgesic. It is a primary aliphatic amine and a member of adamantanes. It is a conjugate base of an adamantan-1-aminium. It derives from a hydride of an adamantane. |
| Classification | Small molecule |
| Drug class | antivirals/antiparkinsonians (adamantane derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC12CC3CC(CC(C3)C1)C2 |
Identifiers
| PDB | — |
| CAS-ID | 768-94-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL660 |
| ChEBI ID | 2618 |
| PubChem CID | 2130 |
| DrugBank | DB00915 |
| UNII ID | BF4C9Z1J53 (ChemIDplus, GSRS) |
Target
Agency Approved
GRIN2B
GRIN2B
Organism
Homo sapiens
Gene name
GRIN2B
Gene synonyms
NMDAR2B
NCBI Gene ID
Protein name
glutamate receptor ionotropic, NMDA 2B
Protein synonyms
GluN2B(alt_5'UTR), Glutamate [NMDA] receptor subunit epsilon-2, glutamate receptor subunit epsilon-2, glutamate receptor, ionotropic, N-methyl D-aspartate 2B, hNR3, N-methyl D-aspartate receptor subtype 2B, N-methyl-D-aspartate receptor subunit 3, NMDAR2B, NR2B, NR3
Uniprot ID
Mouse ortholog
Grin2b (14812)
glutamate receptor ionotropic, NMDA 2B (Q01097)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Osmolex – RVL Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Osmolex – Supernus Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Gocovri – Supernus Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Amantadine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,035 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,318 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use